186 related articles for article (PubMed ID: 35965411)
1. DDX5 mRNA-targeting antisense oligonucleotide as a new promising therapeutic in combating castration-resistant prostate cancer.
Le TK; Cherif C; Omabe K; Paris C; Lannes F; Audebert S; Baudelet E; Hamimed M; Barbolosi D; Finetti P; Bastide C; Fazli L; Gleave M; Bertucci F; Taïeb D; Rocchi P
Mol Ther; 2023 Feb; 31(2):471-486. PubMed ID: 35965411
[TBL] [Abstract][Full Text] [Related]
2. A phase I dose-escalation study of apatorsen (OGX-427), an antisense inhibitor targeting heat shock protein 27 (Hsp27), in patients with castration-resistant prostate cancer and other advanced cancers.
Chi KN; Yu EY; Jacobs C; Bazov J; Kollmannsberger C; Higano CS; Mukherjee SD; Gleave ME; Stewart PS; Hotte SJ
Ann Oncol; 2016 Jun; 27(6):1116-1122. PubMed ID: 27022067
[TBL] [Abstract][Full Text] [Related]
3. Suppression of heat shock protein 27 using OGX-427 induces endoplasmic reticulum stress and potentiates heat shock protein 90 inhibitors to delay castrate-resistant prostate cancer.
Lamoureux F; Thomas C; Yin MJ; Fazli L; Zoubeidi A; Gleave ME
Eur Urol; 2014 Jul; 66(1):145-55. PubMed ID: 24411988
[TBL] [Abstract][Full Text] [Related]
4. Targeting TCTP as a new therapeutic strategy in castration-resistant prostate cancer.
Baylot V; Katsogiannou M; Andrieu C; Taieb D; Acunzo J; Giusiano S; Fazli L; Gleave M; Garrido C; Rocchi P
Mol Ther; 2012 Dec; 20(12):2244-56. PubMed ID: 22893039
[TBL] [Abstract][Full Text] [Related]
5. A randomized phase 2 study of a HSP27 targeting antisense, apatorsen with prednisone versus prednisone alone, in patients with metastatic castration resistant prostate cancer.
Yu EY; Ellard SL; Hotte SJ; Gingerich JR; Joshua AM; Gleave ME; Chi KN
Invest New Drugs; 2018 Apr; 36(2):278-287. PubMed ID: 29250742
[TBL] [Abstract][Full Text] [Related]
6. Menin inhibition suppresses castration-resistant prostate cancer and enhances chemosensitivity.
Cherif C; Nguyen DT; Paris C; Le TK; Sefiane T; Carbuccia N; Finetti P; Chaffanet M; Kaoutari AE; Vernerey J; Fazli L; Gleave M; Manai M; Barthélémy P; Birnbaum D; Bertucci F; Taïeb D; Rocchi P
Oncogene; 2022 Jan; 41(1):125-137. PubMed ID: 34711954
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic Reprogramming with Antisense Oligonucleotides Enhances the Effectiveness of Androgen Receptor Inhibition in Castration-Resistant Prostate Cancer.
Xiao L; Tien JC; Vo J; Tan M; Parolia A; Zhang Y; Wang L; Qiao Y; Shukla S; Wang X; Zheng H; Su F; Jing X; Luo E; Delekta A; Juckette KM; Xu A; Cao X; Alva AS; Kim Y; MacLeod AR; Chinnaiyan AM
Cancer Res; 2018 Oct; 78(20):5731-5740. PubMed ID: 30135193
[TBL] [Abstract][Full Text] [Related]
8.
Luk IS; Shrestha R; Xue H; Wang Y; Zhang F; Lin D; Haegert A; Wu R; Dong X; Collins CC; Zoubeidi A; Gleave ME; Gout PW; Wang Y
Clin Cancer Res; 2017 Mar; 23(6):1542-1551. PubMed ID: 27663589
[No Abstract] [Full Text] [Related]
9. The functional landscape of Hsp27 reveals new cellular processes such as DNA repair and alternative splicing and proposes novel anticancer targets.
Katsogiannou M; Andrieu C; Baylot V; Baudot A; Dusetti NJ; Gayet O; Finetti P; Garrido C; Birnbaum D; Bertucci F; Brun C; Rocchi P
Mol Cell Proteomics; 2014 Dec; 13(12):3585-601. PubMed ID: 25277244
[TBL] [Abstract][Full Text] [Related]
10. Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis.
Rocchi P; Beraldi E; Ettinger S; Fazli L; Vessella RL; Nelson C; Gleave M
Cancer Res; 2005 Dec; 65(23):11083-93. PubMed ID: 16322258
[TBL] [Abstract][Full Text] [Related]
11. Targeting castration-resistant prostate cancer with androgen receptor antisense oligonucleotide therapy.
De Velasco MA; Kura Y; Sakai K; Hatanaka Y; Davies BR; Campbell H; Klein S; Kim Y; MacLeod AR; Sugimoto K; Yoshikawa K; Nishio K; Uemura H
JCI Insight; 2019 Sep; 4(17):. PubMed ID: 31484823
[TBL] [Abstract][Full Text] [Related]
12. Delivery of antisense oligonucleotides for splice-correction of androgen receptor pre-mRNA in castration-resistant prostate cancer models using cell-penetrating peptides.
Luna Velez MV; Paulino da Silva Filho O; Verhaegh GW; van Hooij O; El Boujnouni N; Brock R; Schalken JA
Prostate; 2022 May; 82(6):657-665. PubMed ID: 35098567
[TBL] [Abstract][Full Text] [Related]
13. The MCT4 Gene: A Novel, Potential Target for Therapy of Advanced Prostate Cancer.
Choi SY; Xue H; Wu R; Fazli L; Lin D; Collins CC; Gleave ME; Gout PW; Wang Y
Clin Cancer Res; 2016 Jun; 22(11):2721-33. PubMed ID: 26755530
[TBL] [Abstract][Full Text] [Related]
14. Lipid-oligonucleotide conjugates improve cellular uptake and efficiency of TCTP-antisense in castration-resistant prostate cancer.
Karaki S; Benizri S; Mejías R; Baylot V; Branger N; Nguyen T; Vialet B; Oumzil K; Barthélémy P; Rocchi P
J Control Release; 2017 Jul; 258():1-9. PubMed ID: 28472637
[TBL] [Abstract][Full Text] [Related]
15. OGX-427 inhibits tumor progression and enhances gemcitabine chemotherapy in pancreatic cancer.
Baylot V; Andrieu C; Katsogiannou M; Taieb D; Garcia S; Giusiano S; Acunzo J; Iovanna J; Gleave M; Garrido C; Rocchi P
Cell Death Dis; 2011 Oct; 2(10):e221. PubMed ID: 22012255
[TBL] [Abstract][Full Text] [Related]
16. Investigation of the regulatory effects of synthesized antisense oligonucleotides on androgen receptor (AR) exon 3 splicing in prostate cancer cells.
Wang L; Gong S; Zhang X; Azhar Z; Chen J
Gene; 2023 May; 866():147330. PubMed ID: 36871670
[TBL] [Abstract][Full Text] [Related]
17. RNA-binding protein DDX3 mediates posttranscriptional regulation of androgen receptor: A mechanism of castration resistance.
Vellky JE; McSweeney ST; Ricke EA; Ricke WA
Proc Natl Acad Sci U S A; 2020 Nov; 117(45):28092-28101. PubMed ID: 33106406
[TBL] [Abstract][Full Text] [Related]
18. Heat shock protein 27 as a new therapeutic target for radiation sensitization of head and neck squamous cell carcinoma.
Hadchity E; Aloy MT; Paulin C; Armandy E; Watkin E; Rousson R; Gleave M; Chapet O; Rodriguez-Lafrasse C
Mol Ther; 2009 Aug; 17(8):1387-94. PubMed ID: 19436268
[TBL] [Abstract][Full Text] [Related]
19. Generation 2.5 antisense oligonucleotides targeting the androgen receptor and its splice variants suppress enzalutamide-resistant prostate cancer cell growth.
Yamamoto Y; Loriot Y; Beraldi E; Zhang F; Wyatt AW; Al Nakouzi N; Mo F; Zhou T; Kim Y; Monia BP; MacLeod AR; Fazli L; Wang Y; Collins CC; Zoubeidi A; Gleave M
Clin Cancer Res; 2015 Apr; 21(7):1675-87. PubMed ID: 25634993
[TBL] [Abstract][Full Text] [Related]
20. [Antisense oligodeoxynucleotide therapy for castration-resistant prostate cancer].
Miyake H; Fujisawa M
Nihon Rinsho; 2014 Dec; 72(12):2121-5. PubMed ID: 25518344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
